MaltSci 麦伴科研

Appearance

Popular Reports / Drug Discovery

This report is written by MaltSci based on the latest literature and research findings

How do nanomedicines improve drug delivery? ​

Abstract ​

Nanomedicine is an innovative field that utilizes nanotechnology to enhance drug delivery systems, significantly improving therapeutic efficacy while minimizing adverse side effects. Traditional drug delivery methods often struggle with challenges such as poor solubility and inadequate bioavailability, which nanomedicine effectively addresses through the use of engineered nanoparticles. These nanoscale carriers, including liposomes, dendrimers, and nanoparticles, enhance drug solubility, stability, and targeted delivery, enabling precise administration of therapeutic agents to specific sites in the body. This targeted approach not only improves pharmacokinetics but also reduces systemic toxicity, which is particularly crucial in the treatment of complex diseases like cancer. Furthermore, nanomedicines facilitate the co-delivery of multiple therapeutic agents, enhancing overall treatment outcomes through synergistic effects. Despite the promising advancements, challenges such as biocompatibility, toxicity, and regulatory hurdles remain significant barriers to clinical adoption. As research progresses, addressing these issues will be essential for unlocking the full potential of nanomedicine in drug delivery. This review synthesizes the current state of research in nanomedicine, providing insights into mechanisms of drug delivery improvement, types of nanocarriers, and future perspectives on innovations and clinical applications.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Overview of Nanomedicine
    • 2.1 Definition and Scope
    • 2.2 Historical Development and Milestones
  • 3 Mechanisms of Drug Delivery Improvement
    • 3.1 Enhanced Solubility and Stability
    • 3.2 Targeted Delivery Mechanisms
    • 3.3 Controlled Release Systems
  • 4 Types of Nanocarriers
    • 4.1 Liposomes
    • 4.2 Dendrimers
    • 4.3 Nanoparticles
    • 4.4 Other Emerging Nanocarriers
  • 5 Challenges and Limitations
    • 5.1 Biocompatibility and Toxicity
    • 5.2 Regulatory Issues
    • 5.3 Clinical Translation Barriers
  • 6 Future Perspectives
    • 6.1 Innovations in Nanocarrier Design
    • 6.2 Potential Clinical Applications
    • 6.3 Integration with Other Therapeutic Modalities
  • 7 Conclusion

1 Introduction ​

Nanomedicine represents a revolutionary approach that harnesses the principles of nanotechnology to enhance drug delivery systems, significantly improving therapeutic efficacy while minimizing adverse side effects. The ability to manipulate materials at the nanoscale has opened new avenues for the development of innovative drug delivery mechanisms that can overcome the limitations of traditional pharmacotherapy. Conventional drug delivery methods often face challenges such as poor solubility, inadequate bioavailability, and nonspecific targeting, which can lead to suboptimal therapeutic outcomes. In contrast, nanomedicine offers the potential for targeted and controlled drug delivery, thereby addressing these critical issues and improving patient care[1][2].

The significance of nanomedicine lies not only in its capacity to enhance the effectiveness of existing treatments but also in its potential to revolutionize therapeutic strategies across various medical fields, including oncology, cardiology, and infectious diseases. By enabling the precise delivery of therapeutic agents to specific sites within the body, nanomedicine can enhance the pharmacokinetics and biodistribution of drugs, resulting in improved efficacy and reduced toxicity[3][4]. This capability is particularly crucial in the treatment of complex diseases, such as cancer, where traditional therapies often fall short due to their systemic effects and lack of specificity[5].

Current research in nanomedicine has focused on the development of diverse nanoscale carriers, including liposomes, dendrimers, and nanoparticles, each designed to encapsulate drugs and facilitate their delivery in a controlled manner[2][6]. These nanocarriers possess unique physicochemical properties, such as size, surface charge, and shape, which significantly influence their interaction with biological systems and ultimately determine their effectiveness as drug delivery vehicles[7][8]. For instance, liposomes can enhance the solubility and stability of hydrophobic drugs, while dendrimers offer a multifunctional platform for targeted delivery and controlled release[9][10].

Despite the promising advancements in nanomedicine, several challenges and limitations remain. Issues related to biocompatibility, toxicity, and regulatory hurdles continue to pose significant barriers to the widespread clinical adoption of nanomedicine technologies[11][12]. Moreover, the need for extensive clinical testing to ensure safety and efficacy remains a critical aspect of the development process. As the field progresses, addressing these challenges will be essential to unlocking the full potential of nanomedicine in drug delivery[2][6].

This review is organized into several key sections. First, we will provide an overview of nanomedicine, including its definition, scope, and historical development. Next, we will explore the mechanisms by which nanomedicines improve drug delivery, focusing on enhanced solubility and stability, targeted delivery mechanisms, and controlled release systems. We will then examine various types of nanocarriers, including liposomes, dendrimers, and nanoparticles, as well as emerging nanocarrier technologies. Following this, we will discuss the challenges and limitations associated with nanomedicine, such as biocompatibility and regulatory issues, before concluding with future perspectives on innovations in nanocarrier design and potential clinical applications. By synthesizing the current state of research in nanomedicine, this review aims to inform and inspire further exploration into the transformative potential of nanotechnology in therapeutic strategies[1][2].

2 Overview of Nanomedicine ​

2.1 Definition and Scope ​

Nanomedicine, a rapidly evolving field at the intersection of nanotechnology and medicine, significantly enhances drug delivery systems (DDS) through various innovative approaches. The primary goal of nanomedicine is to improve the efficacy and safety of therapeutic agents by utilizing engineered nanoparticles that can precisely deliver drugs to targeted sites within the body.

One of the key advantages of nanomedicine is its ability to address the limitations of conventional drug delivery methods. Traditional drug delivery systems often face challenges such as poor solubility, limited bioavailability, and systemic toxicity. Nanocarriers, including polymeric nanoparticles, liposomes, dendrimers, and metallic nanoparticles, have emerged as effective solutions to these issues. They improve drug solubility and stability, enhance bioavailability, and enable controlled and sustained release of therapeutic agents [2].

Nanomedicine also employs advanced targeting strategies to ensure that drugs are delivered specifically to diseased tissues while minimizing exposure to healthy tissues. This targeted delivery is achieved through the functionalization of nanocarriers with ligands or antibodies that recognize and bind to specific receptors on the surface of target cells. Such precision not only enhances therapeutic efficacy but also reduces side effects associated with systemic drug distribution [1].

Furthermore, nanomedicine facilitates the co-delivery of multiple therapeutic agents, such as chemotherapeutic drugs and nucleic acids, enhancing the overall therapeutic outcome. This combination strategy allows for synergistic effects, improving the effectiveness of treatments for complex diseases like cancer [1].

In addition to improving drug targeting and efficacy, nanomedicine also optimizes pharmacokinetics—the study of how drugs are absorbed, distributed, metabolized, and excreted in the body. Nanoscale drug delivery systems can prolong the circulation time of drugs in the bloodstream, leading to increased drug retention at the target site and reduced frequency of administration [3].

Recent advancements in nanomedicine include the development of "smart" drug delivery systems that respond to specific stimuli, such as pH changes, temperature, or the presence of certain biomolecules. These systems can release their payload in a controlled manner, providing therapeutic effects precisely when and where they are needed [13].

Moreover, nanomedicine has shown promise in overcoming biological barriers that hinder drug delivery, such as the blood-brain barrier or the pulmonary epithelium. By employing nanoparticles that can navigate these barriers, researchers are exploring new treatment avenues for conditions like brain cancer and respiratory diseases [6].

In summary, nanomedicine significantly enhances drug delivery through improved solubility, targeted delivery, controlled release, and the ability to overcome biological barriers. These advancements not only improve the therapeutic index of drugs but also hold the potential for developing novel treatment strategies for various diseases, thereby transforming the landscape of modern medicine [4][10].

2.2 Historical Development and Milestones ​

Nanomedicine represents a transformative approach in the field of drug delivery, utilizing nanotechnology to enhance the efficacy and precision of therapeutic interventions. The historical development of nanomedicine has been marked by significant milestones that highlight its evolution from conceptual frameworks to practical applications in medicine.

One of the core advancements in nanomedicine is the ability to utilize engineered nanoparticles as drug delivery systems (DDSs). These nanocarriers, including polymeric nanoparticles, liposomes, and metallic nanoparticles, have been designed to overcome the limitations of conventional drug delivery methods. Conventional therapies often face challenges such as poor bioavailability, rapid metabolism, and nonspecific distribution, which can lead to suboptimal therapeutic outcomes and increased side effects. In contrast, nanomedicine enables targeted delivery of therapeutic agents to specific sites in the body, thereby improving the pharmacokinetics and biodistribution of drugs, and reducing toxicity [2].

The application of nanotechnology in drug delivery systems offers several advantages. Nanoparticles can enhance drug solubility and stability, prolong circulation time, and facilitate controlled release of therapeutic agents. For instance, the development of lipid-based prodrug nanocarriers has demonstrated improved drug efficacy by providing sustained release and enhancing chemical stability [9]. Moreover, the ability to engineer the size, shape, and surface characteristics of nanoparticles allows for the optimization of drug uptake and release, particularly across biological barriers such as the blood-brain barrier (BBB) [14].

Nanomedicine also employs innovative combination strategies, such as co-delivery of chemotherapeutic agents with nucleic acids or receptor-specific molecules. This approach not only enhances therapeutic efficacy but also minimizes adverse effects by ensuring that drugs are delivered precisely to the intended target [1]. For example, targeted delivery systems can significantly improve treatment outcomes in conditions such as cancer and chronic inflammatory diseases by ensuring that high concentrations of therapeutic agents are present at the site of action [7].

Furthermore, the advent of DNA nanotechnology has introduced novel methodologies for precise control over drug delivery and gene therapy. This technology leverages the unique properties of nucleic acids to construct nanostructures that can be finely tuned for specific therapeutic applications [15]. Nucleic acid-based nanogels, in particular, have emerged as versatile carriers that respond intelligently to environmental stimuli, further enhancing their utility in targeted therapy [12].

The historical milestones in the development of nanomedicine underscore its rapid progression and the growing recognition of its potential to revolutionize drug delivery. As research continues to advance, the integration of nanotechnology into therapeutic modalities is expected to yield significant improvements in treatment efficacy, safety, and patient outcomes across a range of medical conditions [1][2].

3 Mechanisms of Drug Delivery Improvement ​

3.1 Enhanced Solubility and Stability ​

Nanomedicines represent a transformative approach in drug delivery systems, particularly through their ability to enhance solubility and stability of therapeutic agents. The mechanisms through which nanomedicines improve drug delivery are multifaceted and pivotal for overcoming the limitations associated with traditional drug formulations.

One of the primary mechanisms by which nanomedicines enhance drug delivery is through the improvement of solubility. Many pharmaceutical compounds, particularly those classified as BCS Class II and IV drugs, exhibit poor solubility which significantly limits their bioavailability and therapeutic efficacy. Nanotechnology addresses this challenge by employing various nanoscale drug delivery systems (NDDSs), such as lipid-based carriers, polymer-based systems, nanoemulsions, and nanogels, which facilitate the dissolution of poorly soluble drugs. These nanoscale systems increase the surface area available for dissolution, thereby enhancing the solubility and bioavailability of the drugs. For instance, lipid-based nanocarriers can solubilize hydrophobic drugs effectively, leading to improved absorption in the gastrointestinal tract and enhanced therapeutic outcomes[16].

In addition to solubility enhancement, nanomedicines significantly improve the stability of drugs. Traditional drug formulations often suffer from instability in biological environments, leading to rapid degradation and loss of therapeutic effect. Nanocarriers can encapsulate drugs, providing a protective environment that stabilizes the active ingredients. This encapsulation can prevent premature degradation, ensuring that the drug remains effective until it reaches its target site. Moreover, certain nanocarrier systems can be engineered to allow for controlled release of the drug, thus prolonging its therapeutic action and reducing the frequency of administration[17].

The structural characteristics of nanocarriers also play a crucial role in their ability to enhance drug delivery. The high surface area-to-volume ratio of nanoparticles facilitates better interaction with biological membranes, promoting enhanced permeability and retention effects. This is particularly beneficial in targeting specific tissues or cells, as it allows for more precise drug delivery while minimizing systemic side effects[16].

Furthermore, advancements in nanotechnology have led to the development of stimuli-responsive nanocarriers that can release their payload in response to specific triggers, such as pH changes or the presence of certain enzymes. This targeted approach not only enhances the therapeutic efficacy of the drugs but also reduces toxicity to healthy tissues[1].

In summary, nanomedicines improve drug delivery through enhanced solubility and stability, facilitated by various nanoscale delivery systems. These systems not only address the limitations of traditional drug formulations but also provide innovative strategies for targeted and controlled drug release, ultimately leading to improved therapeutic outcomes and patient compliance. The ongoing research and development in this field continue to unveil new possibilities for effective drug delivery in clinical applications[4][11][18].

3.2 Targeted Delivery Mechanisms ​

Nanomedicine represents a transformative approach in the field of drug delivery, particularly in enhancing the efficacy and specificity of therapeutic agents. The mechanisms by which nanomedicines improve drug delivery can be categorized into several key areas, notably targeted delivery mechanisms.

Targeted delivery mechanisms leverage the unique properties of nanoscale materials to enhance the precision of drug administration. One of the primary advantages of nanomedicine is the ability to deliver therapeutic agents directly to specific sites within the body, thereby increasing the local concentration of the drug at the target site while minimizing systemic exposure and reducing side effects. This is achieved through various strategies, including the use of nanocarriers that can be engineered to respond to specific biological signals or conditions present at the target site.

Nanocarriers such as polymeric nanoparticles, liposomes, and dendrimers can be designed with specific surface modifications that allow them to interact selectively with target cells or tissues. For instance, functionalization of nanoparticles with ligands or antibodies that recognize specific receptors on the surface of target cells can significantly enhance uptake through receptor-mediated endocytosis. This targeted approach not only improves drug bioavailability at the site of action but also enhances therapeutic efficacy by ensuring that higher doses of the drug reach the affected area without impacting healthy tissues [1].

Furthermore, the pharmacokinetics of drugs can be significantly improved through the use of nanomedicines. Nanocarriers can protect drugs from premature degradation in the bloodstream, prolong their circulation time, and facilitate controlled release. For example, the encapsulation of drugs within nanoparticles can prevent rapid clearance by the immune system, allowing for sustained therapeutic effects [2]. Additionally, nanomedicine can address challenges associated with the delivery of poorly soluble drugs by enhancing their solubility and stability in biological fluids [4].

Another significant aspect of targeted delivery mechanisms is the ability to utilize stimuli-responsive systems. These systems can be designed to release their therapeutic payload in response to specific stimuli such as pH changes, temperature variations, or the presence of certain enzymes. This responsiveness ensures that drugs are released precisely at the desired site and time, further enhancing the therapeutic outcomes [10].

In the context of cancer therapy, for instance, nanomedicines have shown great promise in co-delivering chemotherapeutic agents alongside nucleic acids or receptor-specific molecules. This combination strategy not only improves the therapeutic outcomes but also helps in overcoming the limitations of conventional drug delivery methods, such as non-specific toxicity and poor bioavailability [1].

Overall, the integration of nanotechnology in drug delivery systems provides a sophisticated framework for improving the specificity, efficacy, and safety of therapeutic interventions, marking a significant advancement in modern medicine.

3.3 Controlled Release Systems ​

Nanomedicines significantly enhance drug delivery through various mechanisms, particularly by utilizing controlled release systems that improve therapeutic efficacy while minimizing side effects. The advancement of nanocarrier-based drug delivery systems (nDDSs) offers substantial opportunities for improving disease treatment by enhancing drug encapsulation, solubilization, stability, and optimized pharmacokinetics and biodistribution. These systems are composed of lipid, polymeric, protein, and inorganic nanovehicles that can be tailored to respond to biological cues for precise disease management[19].

One of the key features of nDDSs is their ability to incorporate tissue or cell-targeted ligands, which facilitates effective navigation through complex biological environments. This targeted approach ensures that therapeutic agents are delivered specifically to the desired sites, thus augmenting the treatment's efficacy and reducing potential side effects. Furthermore, the functionalization of these nanocarriers with stimuli-responsive moieties enables site-specific controlled release, which is crucial for maximizing therapeutic outcomes[19].

Controlled drug release systems are designed to respond to various endogenous signals such as pH, redox conditions, and enzymatic activity, or external stimuli like light, temperature, and magnetic fields. This allows for a more precise and timely release of the therapeutic agent at the target site, which is particularly beneficial in conditions such as cancer therapy where localized treatment is paramount[20].

Moreover, the integration of nanotechnology in drug delivery has led to the development of "smart" delivery systems that offer multiple levels of targeting and extended-release capabilities. These systems are particularly advantageous in overcoming limitations associated with traditional drug administration, such as reduced solubility, chemoresistance, and systemic toxicity[13]. The application of hybrid nanoparticles, which combine different functional components, has also shown promise in optimizing chemotherapy by improving biosafety, biocompatibility, and multifunctionality[21].

In addition, the use of circulating cells as drug carriers has emerged as a novel approach to enhance targeting efficiency. These living cells possess innate disease sensing and homing properties, which can be harnessed to facilitate more specific and robust drug delivery[22]. The design of these cell-mediated systems includes methods for drug encapsulation and controlled release, which further contribute to the effectiveness of the therapeutic payloads[22].

In summary, nanomedicines improve drug delivery through mechanisms that focus on controlled release systems, targeted delivery, and the utilization of stimuli-responsive technologies. These innovations not only enhance the therapeutic efficacy of drugs but also mitigate adverse effects, thereby paving the way for more effective treatment modalities in various medical fields, particularly in oncology and chronic disease management.

4 Types of Nanocarriers ​

4.1 Liposomes ​

Nanomedicines have revolutionized drug delivery systems, particularly through the use of liposomes as nanocarriers. Liposomes are spherical vesicles composed of phospholipid bilayers, which can encapsulate both hydrophilic and hydrophobic drugs. Their unique structure and properties significantly enhance drug delivery by improving bioavailability, targeting specificity, and controlled release.

One of the primary advantages of liposomes is their ability to enhance the therapeutic efficacy of drugs while minimizing side effects. This is achieved through their capacity to encapsulate therapeutic agents and protect them from degradation in the bloodstream, thus prolonging their circulation time and enhancing their stability. For instance, liposomes can accumulate in tumor tissues due to the enhanced permeability and retention (EPR) effect, which allows for more effective targeting of cancer cells while sparing healthy tissues[23].

Moreover, the design and formulation of liposomes can be tailored to improve their interaction with biological systems. Recent advancements have introduced various strategies to modify liposomal surfaces, including bioconjugation with targeting ligands that can bind specifically to receptors on target cells. This targeted delivery is particularly beneficial in treating heterogeneous diseases such as leukemia, where conventional therapies often face challenges related to drug resistance and systemic toxicity[24].

The development of stimuli-responsive liposomes represents another significant innovation in the field. These liposomes can remain stable in circulation but release their payload in response to specific internal or external stimuli, such as changes in pH, temperature, or the presence of specific enzymes. This mechanism ensures that drugs are released precisely at the target site, further enhancing therapeutic efficacy while reducing off-target effects[25].

Furthermore, liposomes can be utilized in combination therapies, where they co-deliver multiple therapeutic agents, such as chemotherapeutics and gene therapies, enhancing their synergistic effects. This approach is particularly promising in oncology, where the simultaneous delivery of different modalities can improve treatment outcomes and overcome drug resistance[24].

Despite their numerous advantages, challenges remain in the clinical translation of liposomal formulations. Issues such as scalability, immunogenicity, and formulation stability need to be addressed to ensure the successful application of liposomal nanocarriers in clinical settings[24]. Nevertheless, the versatility and adaptability of liposomes as drug delivery systems continue to make them a focal point in the development of nanomedicines aimed at improving patient outcomes across various therapeutic areas, including cancer, cardiovascular diseases, and chronic inflammatory conditions[26].

In summary, liposomes as nanocarriers enhance drug delivery by improving bioavailability, enabling targeted delivery, and allowing for controlled release of therapeutics. Their ability to encapsulate a wide range of drug types, coupled with advancements in their design and formulation, positions them as a crucial component in the evolution of nanomedicine.

4.2 Dendrimers ​

Nanomedicines have significantly transformed drug delivery systems by utilizing various nanocarriers, with dendrimers being one of the most promising types. Dendrimers are hyperbranched macromolecules characterized by their well-defined structure, multivalency, and biocompatibility, making them suitable for a wide range of biomedical applications. They enhance drug delivery through several mechanisms, including improved solubility, targeted delivery, and controlled release.

Dendrimers can encapsulate therapeutic agents, thereby improving their solubility and bioavailability. This is particularly important for hydrophobic drugs that typically have poor solubility in biological fluids. The unique architecture of dendrimers allows for high drug loading capacity, enabling the delivery of sufficient quantities of the drug to the target site. Their structure can be meticulously tailored to accommodate various types of drugs, including small molecules, peptides, and nucleic acids, which enhances the therapeutic efficacy of these agents [27].

Moreover, dendrimers facilitate targeted drug delivery by allowing for the conjugation of targeting ligands that can bind to specific receptors overexpressed on the surface of diseased cells, such as cancer cells. This targeting capability minimizes the exposure of healthy tissues to the drug, thereby reducing side effects and enhancing the overall therapeutic index of the treatment [28].

In addition to targeting capabilities, dendrimers can be engineered to respond to specific stimuli, such as pH or light, which allows for controlled drug release. This feature ensures that the drug is released at the desired location and time, optimizing the therapeutic effect while minimizing potential toxicity [29].

The versatility of dendrimers also extends to their potential in co-delivery systems, where they can simultaneously deliver multiple therapeutic agents, including drugs and genes, enhancing the treatment outcomes for complex diseases such as cancer [30]. Furthermore, advancements in the hybridization of dendrimers with other nanocarriers, such as liposomes and carbon nanotubes, are being explored to create more efficient drug delivery systems that leverage the advantages of both platforms [31].

Overall, dendrimers represent a highly adaptable and effective platform for drug delivery, providing solutions to many of the limitations associated with conventional drug delivery systems. Their unique properties enable enhanced drug solubility, targeted delivery, and controlled release, which are crucial for improving the efficacy and safety of therapeutic interventions in various medical fields, particularly in oncology and gene therapy [2][32].

4.3 Nanoparticles ​

Nanomedicines have significantly transformed drug delivery systems (DDSs) by utilizing engineered nanoparticles as carriers to enhance the therapeutic efficacy of various medications. The unique properties of nanoparticles allow for improved drug bioavailability, controlled release, and targeted delivery, which are critical for effective treatment outcomes.

Nanoparticles can be classified into several types, including polymeric nanoparticles, liposomes, dendrimers, carbon nanotubes, and metallic nanoparticles, each with distinct characteristics and advantages. For instance, polymeric nanoparticles are known for their biocompatibility and ability to encapsulate drugs, thereby protecting them from degradation and enhancing their stability during circulation in the bloodstream[2]. Liposomes, on the other hand, are spherical vesicles that can carry both hydrophilic and hydrophobic drugs, making them versatile carriers for a wide range of therapeutic agents[2].

The mechanism by which nanomedicines improve drug delivery involves several key factors. Firstly, nanoparticles enhance the solubility and absorption of poorly soluble drugs, which is particularly important for achieving therapeutic concentrations in target tissues[4]. By utilizing nanoformulations, the release rates of drugs can be precisely controlled, allowing for sustained therapeutic effects and minimizing side effects associated with conventional drug delivery methods[10].

Moreover, nanoparticles can be engineered to achieve specific targeting through surface functionalization. This involves attaching ligands or antibodies to the nanoparticle surface that can selectively bind to receptors on target cells, thereby enhancing cellular uptake and reducing off-target effects[33]. This targeted approach is particularly beneficial in cancer therapy, where precise delivery of chemotherapeutic agents to tumor cells is essential for maximizing efficacy while minimizing damage to healthy tissues[1].

The development of smart nanocarriers that respond to specific stimuli (e.g., pH, temperature, or light) has further advanced the field of drug delivery. These systems can release their payloads in response to the microenvironment of the disease site, providing a mechanism for localized treatment[34]. Additionally, multifunctional nanoparticles that combine therapeutic agents with imaging capabilities can enable real-time monitoring of drug distribution and therapeutic response[35].

Overall, the incorporation of nanoparticles in drug delivery systems not only enhances the therapeutic profiles of existing medications but also opens avenues for new therapeutic strategies, including combination therapies that integrate multiple modalities for more effective treatment regimens[1][2][33]. As research continues to advance in this area, the potential for nanomedicines to improve patient outcomes and revolutionize treatment paradigms in various diseases remains substantial.

4.4 Other Emerging Nanocarriers ​

Nanomedicines represent a significant advancement in drug delivery systems (DDSs), utilizing engineered nanoparticles to enhance the efficacy and specificity of therapeutic agents. The evolution of nanocarriers has introduced various types that cater to specific therapeutic needs, thus improving drug delivery in multiple ways.

Firstly, nanocarriers such as polymeric nanoparticles, liposomes, dendrimers, and carbon nanotubes offer distinct advantages over conventional drug delivery methods. These nanoparticles operate within the nanoscale range (1-100 nm) and enhance drug efficacy by improving bioavailability, reducing side effects, and enabling targeted delivery to specific sites within the body [36]. For instance, liposomes can encapsulate drugs, providing a protective environment that improves stability and solubility, while also facilitating controlled release at the target site [2].

Nanocarriers also exhibit enhanced drug encapsulation and solubilization properties, which are critical for improving the pharmacokinetics and biodistribution of therapeutic agents. By utilizing materials that are biocompatible and biodegradable, such as synthetic polymers and lipids, these systems can effectively deliver drugs while minimizing adverse effects [10]. The incorporation of stimuli-responsive elements in nanocarriers allows for the controlled release of drugs in response to specific biological cues (e.g., pH, temperature, or enzymatic activity), thereby optimizing therapeutic outcomes [19].

Emerging nanocarriers, such as nanocapsules and solid lipid nanoparticles, further enhance drug delivery by providing improved targeting capabilities. These systems can be functionalized with ligands that bind specifically to receptors on target cells, allowing for precise navigation through complex biological environments [37]. Additionally, multifunctional nanocarriers that respond to external stimuli have been developed to provide site-specific drug release, which is particularly beneficial in treating localized diseases such as cancer [38].

The versatility of nanocarriers also extends to their application in various medical fields, including oncology, neurology, and gene therapy. Nanomedicine has shown promising results in treating diseases like brain cancer and cardiovascular conditions by enhancing drug absorption and reducing the time for therapeutic effects to manifest [2]. Furthermore, the co-delivery of drugs with nucleic acids or other therapeutic agents using nanocarriers is an emerging strategy that holds potential for improving treatment efficacy [1].

In summary, nanomedicines improve drug delivery through a combination of enhanced bioavailability, targeted delivery, controlled release mechanisms, and the ability to overcome biological barriers. The ongoing advancements in nanocarrier technologies continue to pave the way for more effective therapeutic interventions across a wide range of diseases, indicating a promising future for nanomedicine in clinical applications [2][19][36].

5 Challenges and Limitations ​

5.1 Biocompatibility and Toxicity ​

Nanomedicines represent a transformative approach in drug delivery systems, leveraging the unique properties of nanotechnology to enhance the therapeutic efficacy of drugs while addressing significant challenges associated with conventional drug delivery methods. The integration of nanoscale materials allows for improved solubility, bioavailability, and targeted delivery of therapeutic agents, particularly in the treatment of various diseases, including cancer and chronic inflammatory conditions.

One of the primary advantages of nanomedicines is their ability to improve drug solubility and bioavailability. Traditional drug formulations often face challenges related to poor solubility, which can hinder therapeutic efficacy. Nanomedicines, through the use of nanoformulations, enhance the solubility of poorly soluble drugs, thereby facilitating better absorption and utilization by the human body. This enhancement leads to improved drug efficacy and potentially reduced dosages, minimizing side effects on healthy tissues [4].

Moreover, nanomedicine enables targeted drug delivery, allowing for precise administration of therapeutic agents directly to the lesion sites. This targeted approach minimizes systemic exposure and toxicity, as drugs are delivered specifically to affected areas, thus enhancing therapeutic outcomes [3]. For instance, in the context of cancer therapy, nanocarriers can be designed to deliver chemotherapeutic agents in a controlled manner, improving the pharmacokinetics and biodistribution of the drugs while reducing off-target effects [1].

Despite these advancements, several challenges and limitations persist in the field of nanomedicine. One significant concern is the biocompatibility and potential toxicity of nanocarriers. The small size of nanoparticles allows them to navigate biological barriers effectively, but this same property raises questions about their safety and long-term effects within biological systems. There is a risk that nanoparticles could induce unexpected toxicities or accumulate in tissues, leading to adverse health effects [39]. Therefore, understanding the interactions between nanocarriers and biological systems is crucial for ensuring their safety [40].

Additionally, the stability of nanoformulations poses a challenge, as they may undergo degradation or aggregation in biological environments, which can compromise their therapeutic efficacy [37]. Furthermore, the regulatory landscape for nanomedicines is still evolving, presenting hurdles in terms of approval and clinical translation [41].

In conclusion, while nanomedicines offer substantial improvements in drug delivery through enhanced solubility, targeted delivery, and reduced side effects, the field must address significant challenges related to biocompatibility, toxicity, and regulatory approval to fully realize the potential of these innovative therapeutic strategies. Ongoing research and development are essential to optimize the safety and efficacy of nanomedicines in clinical applications.

5.2 Regulatory Issues ​

Nanomedicines enhance drug delivery through various mechanisms, primarily by addressing the limitations associated with traditional drug delivery systems. The application of nanotechnology in medicine enables the development of nanoscale drug delivery systems that significantly improve the pharmacokinetics and biodistribution of therapeutic agents. This improvement results in enhanced bioavailability, solubility, and targeted delivery of drugs, which are crucial for treating diseases effectively.

One of the primary advantages of nanomedicine is its ability to improve drug solubility and bioavailability. Many therapeutic agents, particularly those derived from natural sources, suffer from poor solubility, which limits their effectiveness. Nanoformulations can increase the solubility of these poorly soluble drugs, thereby facilitating better absorption and utilization in the human body. Furthermore, nanomedicine enables targeted drug delivery, ensuring that therapeutic agents are delivered directly to the site of action while minimizing side effects on healthy tissues. This targeted approach is particularly beneficial in the treatment of cancer, where the aim is to deliver drugs specifically to tumor cells while sparing normal cells [1].

Moreover, nanomedicine allows for the regulation of drug release rates, extending the duration of therapeutic action and enhancing the stability of treatment effects. For instance, nanoparticles can be engineered to release their payload in a controlled manner, responding to specific stimuli within the body, such as pH changes or the presence of certain enzymes [42].

Despite these advancements, several challenges and limitations hinder the full realization of nanomedicine's potential. One significant challenge is the complexity of biological systems, which can create barriers to effective drug delivery. For example, physiological barriers such as blood circulation and cellular barriers can prevent drugs from reaching their intended targets [20]. Additionally, the long-term safety and stability of nanoformulations are still under investigation, with concerns regarding potential toxicity and immune responses arising from their use [43].

Regulatory issues also pose significant challenges to the development and clinical translation of nanomedicines. The lack of a specific regulatory framework for nanoformulations has created gaps in the requirements necessary for their approval. This absence complicates the assessment of safety and efficacy, as the unique physicochemical properties of nanoparticles necessitate additional testing and evaluation processes [44]. Researchers often face difficulties in establishing evidence that can be extrapolated from in vitro studies to in vivo applications, further complicating the regulatory landscape [45].

To improve the success of nanomedicines, it is essential to address these regulatory challenges by developing comprehensive guidelines that account for the unique characteristics of nanotechnology-based products. This includes ensuring that safety, quality, and efficacy testing are adequately tailored to the specific needs of nanoparticle formulations [46]. A thorough understanding of the critical quality attributes related to the formulation and biological performance of these systems will facilitate their clinical translation [11].

In summary, while nanomedicines hold great promise for improving drug delivery through enhanced solubility, bioavailability, and targeted action, they also face significant challenges related to biological barriers and regulatory frameworks. Addressing these issues is crucial for the successful integration of nanomedicine into clinical practice.

5.3 Clinical Translation Barriers ​

Nanomedicines represent a significant advancement in drug delivery systems, primarily due to their ability to enhance the therapeutic efficacy of drugs while minimizing adverse effects. The unique properties of nanoparticles, such as their small size, large surface area, and customizable surface characteristics, allow for improved solubility, stability, and bioavailability of therapeutic agents. The concept of the enhanced permeability and retention (EPR) effect is fundamental to nanomedicine, enabling targeted drug delivery to diseased tissues, particularly in cancer therapy [47].

However, despite the promising potential of nanomedicines, several challenges and limitations hinder their effective clinical translation. One major challenge is the inconsistency between preclinical and clinical outcomes. While many nanoparticle-based delivery systems show favorable results in vitro and in animal models, these results often do not translate effectively to human trials. Factors contributing to this gap include the oversimplification of the EPR effect, variability in biological responses among different species, and the complex physiological barriers encountered during systemic delivery [48].

Furthermore, the physicochemical properties of nanoparticles, such as their size, shape, and surface chemistry, significantly influence their behavior in biological systems. Poor understanding of these properties can lead to suboptimal design and formulation of nanomedicines, which may not achieve the desired therapeutic outcomes in patients [49]. Additionally, biocompatibility concerns and the potential for toxicity pose significant barriers, as the safety profiles of many nanomedicines are still under investigation [50].

Regulatory challenges also play a critical role in the clinical translation of nanomedicines. The lack of standardized guidelines for the approval of nanomedicine products complicates the pathway from laboratory research to clinical application. This regulatory uncertainty can deter investment and slow down the development process [51].

Moreover, manufacturing scalability presents another hurdle. The processes required to produce nanomedicines at a scale suitable for clinical use must be robust and reproducible. Variability in production can lead to differences in the therapeutic effectiveness and safety of the final product [11].

In conclusion, while nanomedicines hold great promise for improving drug delivery and enhancing treatment outcomes, several challenges remain that must be addressed to facilitate their successful clinical translation. These include bridging the gap between preclinical and clinical efficacy, ensuring biocompatibility and safety, navigating regulatory frameworks, and establishing scalable manufacturing processes. Addressing these barriers will be crucial for realizing the full potential of nanomedicine in clinical practice [1].

6 Future Perspectives ​

6.1 Innovations in Nanocarrier Design ​

Nanomedicines represent a transformative approach in drug delivery systems (DDS), enhancing the efficacy and safety of therapeutic agents through innovative nanocarrier designs. The application of nanotechnology in medicine has led to the development of various engineered nanoparticles that address significant challenges associated with conventional drug delivery methods, such as poor bioavailability, rapid degradation, and off-target effects.

One of the primary advantages of nanomedicines is their ability to improve drug bioavailability and solubility. Nanocarriers, such as polymeric nanoparticles, liposomes, and dendrimers, are designed to encapsulate drugs, protecting them from degradation and facilitating their transport across biological barriers. For instance, the use of engineered nanoparticles allows for controlled release and targeted delivery, ensuring that therapeutic agents reach their intended sites of action with minimal systemic exposure [2].

Moreover, nanomedicines have shown significant promise in enhancing the pharmacokinetics of drugs. By modifying the surface properties of nanocarriers, researchers can increase their affinity for specific cell types, thus improving targeting accuracy. This targeted approach reduces the likelihood of side effects associated with non-specific distribution of drugs [1]. The development of multifunctional nanocarriers that can co-deliver therapeutic agents, such as chemotherapeutic drugs alongside nucleic acids, further exemplifies the innovative strategies being employed to enhance therapeutic outcomes in cancer treatment [52].

In terms of future perspectives, the design of nanocarriers is expected to evolve with advancements in materials science and nanotechnology. Innovative strategies, including biomimetic approaches that mimic natural processes, are being explored to create more effective and biocompatible drug delivery systems [37]. The integration of artificial intelligence with nanotechnology is also anticipated to drive the next generation of nanocarrier systems, enabling the design of personalized therapies that can adapt to individual patient needs [52].

Additionally, the challenges of delivering therapeutic agents across biological barriers, such as the blood-brain barrier or mucosal surfaces, are being addressed through the development of novel nanocarrier designs. For example, specific surface modifications and the use of stimuli-responsive materials can enhance the permeability and retention of drugs at target sites, thereby improving treatment efficacy [53].

In summary, nanomedicines significantly improve drug delivery through enhanced bioavailability, targeted delivery, and controlled release mechanisms. The future of nanocarrier design lies in innovative approaches that leverage advanced materials and technologies to overcome existing challenges, ultimately leading to more effective and safer therapeutic interventions. The continuous evolution of this field promises to expand the horizons of medicine, providing novel solutions for complex health issues.

6.2 Potential Clinical Applications ​

Nanomedicines significantly enhance drug delivery through several innovative mechanisms and technologies that address the limitations of conventional therapeutic approaches. The application of nanotechnology in medicine, particularly in drug delivery systems (DDS), has emerged as a transformative strategy for improving therapeutic efficacy and minimizing adverse effects.

One of the primary advantages of nanomedicines is their ability to achieve targeted drug delivery. This precision allows therapeutic agents to be directed specifically to diseased tissues while sparing healthy cells, thereby reducing systemic toxicity and enhancing treatment outcomes. For instance, targeted drug delivery via nanocarriers has shown substantial improvements in pharmacokinetics, specificity, and biocompatibility, leading to more effective therapies with fewer side effects [1]. The design of these nanocarriers, which include liposomes, dendrimers, and polymeric nanoparticles, allows for the encapsulation of drugs, ensuring controlled release and improved stability in biological environments [3].

Nanomedicines also facilitate the co-delivery of multiple therapeutic agents, such as chemotherapeutic drugs alongside nucleic acids or receptor-specific molecules. This combination strategy enhances therapeutic outcomes by simultaneously addressing different pathways involved in disease progression [1]. For example, the incorporation of active pharmaceutical ingredients from medicinal plants into nanoformulations can significantly improve their solubility and bioavailability, thereby enhancing their therapeutic efficacy [4].

Moreover, the nanoscale nature of these delivery systems allows for improved biodistribution of therapeutic agents, which is particularly crucial in treating critical illnesses. Nanoparticles can effectively navigate biological barriers, ensuring that drugs reach their intended sites of action in a controlled manner [3]. This is especially relevant in conditions like sepsis or acute respiratory distress syndrome, where targeted delivery can significantly improve therapeutic efficacy [3].

In terms of future perspectives, the ongoing development of advanced nanocarriers is poised to further refine drug delivery systems. Innovations such as stimuli-responsive nanocarriers, which release their payload in response to specific biological triggers, are expected to enhance the specificity and effectiveness of treatments [8]. Additionally, the integration of nanomedicines with regenerative medicine is being explored, particularly for improving tissue repair and regeneration through controlled delivery of therapeutic proteins and stem cells [54].

Potential clinical applications of nanomedicines are vast and include the treatment of chronic diseases such as cancer, diabetes, and neurodegenerative disorders. The ability of nanocarriers to encapsulate a wide range of therapeutic agents, including small molecules, peptides, and nucleic acids, positions them as versatile tools in modern medicine [55]. Several nanomedicines have already gained regulatory approval and are in clinical use, demonstrating their viability in real-world applications [56].

In conclusion, nanomedicines represent a significant advancement in drug delivery, offering targeted, efficient, and safer therapeutic options. The continued exploration of nanotechnology in medicine holds promise for addressing complex medical challenges and improving patient outcomes across a range of diseases.

6.3 Integration with Other Therapeutic Modalities ​

Nanomedicines represent a significant advancement in drug delivery systems, leveraging the unique properties of nanoscale materials to enhance the efficacy and precision of therapeutic interventions. The integration of nanotechnology with other therapeutic modalities holds promising potential for improving drug delivery and therapeutic outcomes.

One of the primary advantages of nanomedicines is their ability to improve the solubility and bioavailability of therapeutic agents, particularly those that are poorly soluble in conventional formulations. This is particularly relevant in the context of natural products and plant-derived compounds, where nanoformulations can enhance the absorption and utilization of active pharmaceutical ingredients, thereby improving their therapeutic efficacy[4]. Furthermore, nanomedicine facilitates targeted drug delivery, ensuring that therapeutic agents are delivered precisely to the lesion sites while minimizing exposure to healthy tissues, which is crucial for reducing side effects and improving patient outcomes[1].

Nanocarriers, such as polymeric nanoparticles, liposomes, and dendrimers, can be engineered to achieve specific targeting and controlled release profiles. For instance, recent advancements in "smart" drug delivery systems incorporate stimuli-responsive mechanisms that allow for the release of therapeutic agents in response to specific environmental triggers, such as pH changes or the presence of certain biomarkers[13]. This level of control enhances the therapeutic index of drugs, particularly in cancer therapy, where combination strategies that co-deliver chemotherapeutic agents with nucleic acids or receptor-specific molecules have shown significant improvements in therapeutic outcomes[1].

The future perspectives for nanomedicine are closely tied to its integration with other therapeutic modalities. The combination of nanomedicine with biologics, such as monoclonal antibodies and gene therapies, offers a novel approach to personalized medicine. By tailoring drug delivery systems to individual patient profiles, it is possible to achieve more effective treatments with reduced toxicity[57]. Moreover, the use of wearable drug delivery devices in conjunction with nanomedicine can facilitate continuous monitoring and adjustment of therapy, thereby enhancing treatment compliance and efficacy[57].

Furthermore, the integration of nanotechnology with diagnostic tools, known as theranostics, allows for simultaneous diagnosis and treatment, which is particularly beneficial in managing complex diseases like cancer. This convergence enhances the precision of drug delivery, enabling clinicians to adapt treatment strategies based on real-time feedback from diagnostic assessments[57].

In summary, nanomedicines significantly improve drug delivery through enhanced solubility, targeted delivery, and controlled release mechanisms. The future of nanomedicine lies in its integration with other therapeutic modalities, paving the way for personalized, precise, and effective treatment strategies that can transform the management of various diseases, including cancer and chronic conditions. The ongoing research and development in this field are expected to yield innovative solutions that address current limitations in drug delivery systems, ultimately improving patient care and treatment outcomes.

7 Conclusion ​

Nanomedicine represents a transformative advancement in drug delivery systems, offering solutions to many of the limitations faced by traditional pharmacotherapy. Key findings highlight that nanocarriers such as liposomes, dendrimers, and nanoparticles significantly enhance drug solubility, bioavailability, and targeted delivery, thus improving therapeutic efficacy while minimizing side effects. Current research indicates that these nanoscale systems not only facilitate controlled release mechanisms but also possess the capability to overcome biological barriers, enhancing treatment options for complex diseases such as cancer. However, challenges remain in the areas of biocompatibility, toxicity, and regulatory approval, which must be addressed to facilitate the clinical translation of nanomedicines. Future research directions should focus on the development of innovative nanocarrier designs, integration with other therapeutic modalities, and the establishment of robust regulatory frameworks to ensure safety and efficacy. The ongoing evolution of nanomedicine promises to significantly impact patient care and therapeutic strategies across various medical fields, marking a pivotal shift in modern medicine.

References ​

  • [1] Rupesh K Gautam;Pooja Mittal;Rajat Goyal;Kamal Dua;Dinesh Kumar Mishra;Sanjay Sharma;Rajeev Kumar Singla. Nanomedicine: Innovative Strategies and Recent Advances in Targeted Cancer Therapy.. Current medicinal chemistry(IF=3.5). 2024. PMID:37828674. DOI: 10.2174/0109298673258987231004092334.
  • [2] Obaid Afzal;Abdulmalik S A Altamimi;Muhammad Shahid Nadeem;Sami I Alzarea;Waleed Hassan Almalki;Aqsa Tariq;Bismillah Mubeen;Bibi Nazia Murtaza;Saima Iftikhar;Naeem Riaz;Imran Kazmi. Nanoparticles in Drug Delivery: From History to Therapeutic Applications.. Nanomaterials (Basel, Switzerland)(IF=4.3). 2022. PMID:36558344. DOI: 10.3390/nano12244494.
  • [3] Ruxana T Sadikot. The potential role of nano- and micro-technology in the management of critical illnesses.. Advanced drug delivery reviews(IF=17.6). 2014. PMID:25204519. DOI: .
  • [4] Yuhao Chen;Yuying Tang;Yuanbo Li;Yukui Rui;Peng Zhang. Enhancing the Efficacy of Active Pharmaceutical Ingredients in Medicinal Plants through Nanoformulations: A Promising Field.. Nanomaterials (Basel, Switzerland)(IF=4.3). 2024. PMID:39404324. DOI: 10.3390/nano14191598.
  • [5] Mónica Rivera Díaz;Pablo E Vivas-Mejia. Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes.. Pharmaceuticals (Basel, Switzerland)(IF=4.8). 2013. PMID:24287462. DOI: 10.3390/ph6111361.
  • [6] Hulda Swai;Boitumelo Semete;Lonji Kalombo;Paul Chelule;Kevin Kisich;Bob Sievers. Nanomedicine for respiratory diseases.. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology(IF=8.2). 2009. PMID:20049795. DOI: 10.1002/wnan.33.
  • [7] Sujata Maurya;Rashi Srivastava;Saniya Arfin;Susan Hawthorne;Niraj Kumar Jha;Kirti Agrawal;Sibi Raj;Brijesh Rathi;Arun Kumar;Riya Raj;Sharad Agrawal;Ana Cláudia Paiva-Santos;Asrar Ahmad Malik;Kamal Dua;Rakesh Rana;Shreesh Ojha;Saurabh Kumar Jha;Ankur Sharma;Dhruv Kumar;Sally A El-Zahaby;Amka Nagar. Exploring state-of-the-art advances in targeted nanomedicines for managing acute and chronic inflammatory lung diseases.. Nanomedicine (London, England)(IF=3.9). 2022. PMID:36975758. DOI: 10.2217/nnm-2021-0437.
  • [8] Shi Su;Peter M Kang. Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems.. Pharmaceutics(IF=5.5). 2020. PMID:32882875. DOI: 10.3390/pharmaceutics12090837.
  • [9] Simona Mura;Duc Trung Bui;Patrick Couvreur;Julien Nicolas. Lipid prodrug nanocarriers in cancer therapy.. Journal of controlled release : official journal of the Controlled Release Society(IF=11.5). 2015. PMID:25617724. DOI: .
  • [10] Sumera Khizar;Noor Alrushaid;Firdos Alam Khan;Nadia Zine;Nicole Jaffrezic-Renault;Abdelhamid Errachid;Abdelhamid Elaissari. Nanocarriers based novel and effective drug delivery system.. International journal of pharmaceutics(IF=5.2). 2023. PMID:36587775. DOI: 10.1016/j.ijpharm.2022.122570.
  • [11] Maie S Taha;Smrithi Padmakumar;Amit Singh;Mansoor M Amiji. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.. Drug delivery and translational research(IF=5.5). 2020. PMID:32170656. DOI: 10.1007/s13346-020-00744-1.
  • [12] Zijian Zhao;Fei Sun;Hongli Yu;Bing Li;Xianwen Wang;Yong Sun;Jianqin Yan. Nucleic acid-based nanogels for drug delivery：From construction strategies to intelligent applications.. Colloids and surfaces. B, Biointerfaces(IF=5.6). 2025. PMID:40663864. DOI: 10.1016/j.colsurfb.2025.114948.
  • [13] Regina-Veronicka Kalaydina;Komal Bajwa;Bessi Qorri;Alexandria Decarlo;Myron R Szewczuk. Recent advances in "smart" delivery systems for extended drug release in cancer therapy.. International journal of nanomedicine(IF=6.5). 2018. PMID:30154657. DOI: 10.2147/IJN.S168053.
  • [14] Ari Nowacek;Howard E Gendelman. NanoART, neuroAIDS and CNS drug delivery.. Nanomedicine (London, England)(IF=3.9). 2009. PMID:19572821. DOI: 10.2217/nnm.09.38.
  • [15] Chava Angell;Sibai Xie;Liangfang Zhang;Yi Chen. DNA Nanotechnology for Precise Control over Drug Delivery and Gene Therapy.. Small (Weinheim an der Bergstrasse, Germany)(IF=12.1). 2016. PMID:26725041. DOI: 10.1002/smll.201502167.
  • [16] Yifan Liu;Yushan Liang;Jing Yuhong;Peng Xin;Jia Li Han;Yongle Du;Xinru Yu;Runhe Zhu;Mingxun Zhang;Wen Chen;Yingjie Ma. Advances in Nanotechnology for Enhancing the Solubility and Bioavailability of Poorly Soluble Drugs.. Drug design, development and therapy(IF=5.1). 2024. PMID:38707615. DOI: 10.2147/DDDT.S447496.
  • [17] Kalpesh Mahajan;Sankha Bhattacharya. The Advancement and Obstacles in Improving the Stability of Nanocarriers for Precision Drug Delivery in the Field of Nanomedicine.. Current topics in medicinal chemistry(IF=3.3). 2024. PMID:38409730. DOI: 10.2174/0115680266287101240214071718.
  • [18] Amit Alexander; Ajazuddin;Ravish J Patel;Swarnlata Saraf;Shailendra Saraf. Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives.. Journal of controlled release : official journal of the Controlled Release Society(IF=11.5). 2016. PMID:27663228. DOI: 10.1016/j.jconrel.2016.09.017.
  • [19] Yuqian Wang;Renqi Huang;Shufan Feng;Ran Mo. Advances in nanocarriers for targeted drug delivery and controlled drug release.. Chinese journal of natural medicines(IF=4.9). 2025. PMID:40383609. DOI: 10.1016/S1875-5364(25)60861-2.
  • [20] Shiyi Huang;Xianting Ding. Precise Design Strategies of Nanotechnologies for Controlled Drug Delivery.. Journal of functional biomaterials(IF=5.2). 2022. PMID:36278656. DOI: 10.3390/jfb13040188.
  • [21] Menghuan Li;Zhong Luo;Yanli Zhao. Hybrid Nanoparticles as Drug Carriers for Controlled Chemotherapy of Cancer.. Chemical record (New York, N.Y.)(IF=7.5). 2016. PMID:27258402. DOI: 10.1002/tcr.201600029.
  • [22] Yixue Su;Zhiwei Xie;Gloria B Kim;Cheng Dong;Jian Yang. Design strategies and applications of circulating cell-mediated drug delivery systems.. ACS biomaterials science & engineering(IF=5.5). 2015. PMID:25984572. DOI: 10.1021/ab500179h.
  • [23] Jiayi Chen;Siyuan Hu;Man Sun;Jianan Shi;Huan Zhang;Hongmei Yu;Zhaogang Yang. Recent advances and clinical translation of liposomal delivery systems in cancer therapy.. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences(IF=4.7). 2024. PMID:38171420. DOI: 10.1016/j.ejps.2023.106688.
  • [24] Anil Pareek;Ali M Alaseem;Glowi Alasiri;Devesh U Kapoor;Bhupendra G Prajapati. Stimuli-responsive liposomes and niosomes in leukemia therapy: targeted delivery and clinical translation.. International journal of pharmaceutics(IF=5.2). 2025. PMID:40975447. DOI: 10.1016/j.ijpharm.2025.126169.
  • [25] Marjan Abri Aghdam;Roya Bagheri;Jafar Mosafer;Behzad Baradaran;Mahmoud Hashemzaei;Amir Baghbanzadeh;Miguel de la Guardia;Ahad Mokhtarzadeh. Recent advances on thermosensitive and pH-sensitive liposomes employed in controlled release.. Journal of controlled release : official journal of the Controlled Release Society(IF=11.5). 2019. PMID:31647978. DOI: 10.1016/j.jconrel.2019.09.018.
  • [26] Hongnv Zhang;Nan Hu;Zhenghao Wang;Shaodong Zhai. Liposome-mediated macrophage reprogramming: emerging strategies for chronic disease therapy.. Frontiers in immunology(IF=5.9). 2025. PMID:41181144. DOI: 10.3389/fimmu.2025.1653642.
  • [27] Michał Gorzkiewicz;Barbara Klajnert-Maculewicz. Dendrimers as nanocarriers for nucleoside analogues.. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V(IF=4.3). 2017. PMID:28089915. DOI: 10.1016/j.ejpb.2016.12.030.
  • [28] Prashant Kesharwani;Arun K Iyer. Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery.. Drug discovery today(IF=7.5). 2015. PMID:25555748. DOI: .
  • [29] Mehdi Rajabi;Hossein Feyzbakhsh. Polymeric nanocarriers in drug delivery, bioimaging, and biosensing: advances and perspectives on nanomicelles, nanogels, and dendrimers.. RSC advances(IF=4.6). 2025. PMID:41140492. DOI: 10.1039/d5ra05399d.
  • [30] Fereydoon Abedi-Gaballu;Gholamreza Dehghan;Maryam Ghaffari;Reza Yekta;Soheil Abbaspour-Ravasjani;Behzad Baradaran;Jafar Ezzati Nazhad Dolatabadi;Michael R Hamblin. PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy.. Applied materials today(IF=6.9). 2018. PMID:30511014. DOI: 10.1016/j.apmt.2018.05.002.
  • [31] Prashant Kesharwani;Avinash Gothwal;Arun K Iyer;Keerti Jain;Manish K Chourasia;Umesh Gupta. Dendrimer nanohybrid carrier systems: an expanding horizon for targeted drug and gene delivery.. Drug discovery today(IF=7.5). 2018. PMID:28697371. DOI: 10.1016/j.drudis.2017.06.009.
  • [32] Hao-Jui Hsu;Jason Bugno;Seung-Ri Lee;Seungpyo Hong. Dendrimer-based nanocarriers: a versatile platform for drug delivery.. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology(IF=8.2). 2017. PMID:27126551. DOI: 10.1002/wnan.1409.
  • [33] Mahfoozur Rahman;Janhvi Singh;Alhussain Aodah;Majed Alrobaian;Nabil K Alruwaili;Waleed H Almalki;Salem Salman Almujri;Safia Obaidur Rab;Osama A Madkhali;Ankit Sahoo;Jonathan A Lal. Chiral nanosystem and chiral supraparticles for drug delivery: an expert opinion.. Expert opinion on drug delivery(IF=5.4). 2025. PMID:39688614. DOI: 10.1080/17425247.2024.2444347.
  • [34] Shweta Rai;Neeraj Singh;Sankha Bhattacharya. Concepts on Smart Nano-Based Drug Delivery System.. Recent patents on nanotechnology(IF=3.1). 2022. PMID:33494685. DOI: 10.2174/1872210515666210120113738.
  • [35] Istvan Szelenyi. Nanomedicine: evolutionary and revolutionary developments in the treatment of certain inflammatory diseases.. Inflammation research : official journal of the European Histamine Research Society ... et al.. 2012. PMID:22057873. DOI: 10.1007/s00011-011-0393-7.
  • [36] Atish Kumar S Mundada;Lokesh P Kothari;Kuldeep Vinchurkar;Saloni Yadav;Arprita Malhan;Mridul Guleria;Sudarshan Singh. Advancements in Nanocarrier Production Techniques and Methods for Enhanced Targeted Delivery of Drug: A Comprehensive Review.. Current drug delivery(IF=3.0). 2025. PMID:40754880. DOI: 10.2174/0115672018379860250722161458.
  • [37] Runzi Guo;Zhenzhen Zhang;Shuyi Zhang;Tingting Gai;Huizhu Yu;Li Su;Heng Yin;Xiuhui Wang;Yafeng Zhang. Innovative nanocarriers: Synthetic and biomimetic strategies for enhanced drug delivery.. Materials today. Bio(IF=10.2). 2025. PMID:40838213. DOI: 10.1016/j.mtbio.2025.102180.
  • [38] Joydeb Majumder;Tamara Minko. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery.. Expert opinion on drug delivery(IF=5.4). 2021. PMID:32969740. DOI: 10.1080/17425247.2021.1828339.
  • [39] Andreas M Nyström;Bengt Fadeel. Safety assessment of nanomaterials: implications for nanomedicine.. Journal of controlled release : official journal of the Controlled Release Society(IF=11.5). 2012. PMID:22306428. DOI: 10.1016/j.jconrel.2012.01.027.
  • [40] Adewale O Oladipo;Sogolo L Lebelo;Titus A M Msagati. Nanocarrier design-function relationship: The prodigious role of properties in regulating biocompatibility for drug delivery applications.. Chemico-biological interactions(IF=5.4). 2023. PMID:37004951. DOI: 10.1016/j.cbi.2023.110466.
  • [41] Chinedu O Egwu;Chinyere Aloke;Kenneth T Onwe;Chukwunalu Igbudu Umoke;Joseph Nwafor;Robert A Eyo;Jennifer Adaeze Chukwu;Godswill O Ufebe;Jennifer Ladokun;David Tersoo Audu;Anthony O Agwu;David Chukwu Obasi;Chukwuemeka O Okoro. Nanomaterials in Drug Delivery: Strengths and Opportunities in Medicine.. Molecules (Basel, Switzerland)(IF=4.6). 2024. PMID:38893460. DOI: 10.3390/molecules29112584.
  • [42] Pratikeswar Panda;Shreyashree Mohanty;Sangita Ranee Gouda;Rajaram Mohapatra. Advances in nanomedicine for retinal drug delivery: overcoming barriers and enhancing therapeutic outcomes.. Journal of drug targeting(IF=3.9). 2025. PMID:39694681. DOI: 10.1080/1061186X.2024.2443144.
  • [43] Weijia Lu;Jing Yao;Xiao Zhu;Yi Qi. Nanomedicines: Redefining traditional medicine.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie(IF=7.5). 2021. PMID:33338747. DOI: 10.1016/j.biopha.2020.111103.
  • [44] Anna Salvati;Klaas Poelstra. Drug Targeting and Nanomedicine: Lessons Learned from Liver Targeting and Opportunities for Drug Innovation.. Pharmaceutics(IF=5.5). 2022. PMID:35057111. DOI: 10.3390/pharmaceutics14010217.
  • [45] Thelvia I Ramos;Carlos A Villacis-Aguirre;Katherine V López-Aguilar;Leandro Santiago Padilla;Claudia Altamirano;Jorge R Toledo;Nelson Santiago Vispo. The Hitchhiker's Guide to Human Therapeutic Nanoparticle Development.. Pharmaceutics(IF=5.5). 2022. PMID:35213980. DOI: 10.3390/pharmaceutics14020247.
  • [46] Louise Lacalendola Tundisi;Janaína Artem Ataide;Juliana Souza Ribeiro Costa;Diego de Freitas Coêlho;Raquel Bester Liszbinski;André Moreni Lopes;Laura Oliveira-Nascimento;Marcelo Bispo de Jesus;Angela Faustino Jozala;Carsten Ehrhardt;Priscila Gava Mazzola. Nanotechnology as a tool to overcome macromolecules delivery issues.. Colloids and surfaces. B, Biointerfaces(IF=5.6). 2023. PMID:36455361. DOI: 10.1016/j.colsurfb.2022.113043.
  • [47] Farah Rehan;Mingjie Zhang;Jun Fang;Khaled Greish. Therapeutic Applications of Nanomedicine: Recent Developments and Future Perspectives.. Molecules (Basel, Switzerland)(IF=4.6). 2024. PMID:38731563. DOI: 10.3390/molecules29092073.
  • [48] Rachna Nayak;Igor Meerovich;Alekha K Dash. Translational Multi-Disciplinary Approach for the Drug and Gene Delivery Systems for Cancer Treatment.. AAPS PharmSciTech(IF=4.0). 2019. PMID:30968269. DOI: 10.1208/s12249-019-1367-2.
  • [49] Paul Joyce;Christine J Allen;María José Alonso;Marianne Ashford;Michelle S Bradbury;Matthieu Germain;Maria Kavallaris;Robert Langer;Twan Lammers;Maria Teresa Peracchia;Amirali Popat;Clive A Prestidge;Cristianne J F Rijcken;Bruno Sarmento;Ruth B Schmid;Avi Schroeder;Santhni Subramaniam;Chelsea R Thorn;Kathryn A Whitehead;Chun-Xia Zhao;Hélder A Santos. A translational framework to DELIVER nanomedicines to the clinic.. Nature nanotechnology(IF=34.9). 2024. PMID:39242807. DOI: 10.1038/s41565-024-01754-7.
  • [50] Jacopo Venturini;Abhijit Chakraborty;Mehmet A Baysal;Apostolia M Tsimberidou. Developments in nanotechnology approaches for the treatment of solid tumors.. Experimental hematology & oncology(IF=13.5). 2025. PMID:40390104. DOI: 10.1186/s40164-025-00656-1.
  • [51] Virendra Kumar Yadav;Shazia Tahira;Renuka Jyothi;Pankaj Kumar;Karthikeyan Jayabalan;Nisha Choudhary;Rakesh Kumar Verma;Ashish Patel;Rustem Zairov. Breaking Through Barriers: The Transformative Potential of Nanomedicine in Overcoming Drug Delivery Challenges for Psychiatric Disorders.. CNS & neurological disorders drug targets(IF=3.0). 2025. PMID:41193454. DOI: 10.2174/0118715273384176250929130818.
  • [52] Minhye Kim;Myeongyeon Shin;Yaping Zhao;Mrinmoy Ghosh;Young-Ok Son. Transformative Impact of Nanocarrier-Mediated Drug Delivery: Overcoming Biological Barriers and Expanding Therapeutic Horizons.. Small science(IF=8.3). 2024. PMID:40213439. DOI: 10.1002/smsc.202400280.
  • [53] Maria José Alonso. Nanomedicines for overcoming biological barriers.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie(IF=7.5). 2004. PMID:15082339. DOI: 10.1016/j.biopha.2004.01.007.
  • [54] Elisa Garbayo;Simon Pascual-Gil;Carlos Rodríguez-Nogales;Laura Saludas;Ander Estella-Hermoso de Mendoza;Maria J Blanco-Prieto. Nanomedicine and drug delivery systems in cancer and regenerative medicine.. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology(IF=8.2). 2020. PMID:32351045. DOI: 10.1002/wnan.1637.
  • [55] Akhand Pratap Singh;Arpan Biswas;Aparna Shukla;Pralay Maiti. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles.. Signal transduction and targeted therapy(IF=52.7). 2019. PMID:31637012. DOI: 10.1038/s41392-019-0068-3.
  • [56] Fahima Dilnawaz;Sarbari Acharya;Sanjeeb Kumar Sahoo. Recent trends of nanomedicinal approaches in clinics.. International journal of pharmaceutics(IF=5.2). 2018. PMID:29339248. DOI: 10.1016/j.ijpharm.2018.01.016.
  • [57] Matteo Puccetti;Marilena Pariano;Aurélie Schoubben;Stefano Giovagnoli;Maurizio Ricci. Biologics, theranostics, and personalized medicine in drug delivery systems.. Pharmacological research(IF=10.5). 2024. PMID:38295917. DOI: 10.1016/j.phrs.2024.107086.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Nanomedicine · Drug Delivery · Targeted Therapy · Nanocarriers · Biocompatibility

© 2025 MaltSci